Eric D. Shaff

Insider Reports History

Entity
Individual
Location
C/O Seres Health, Inc., 161 First Street, Cambridge, MA
Signature
/s/ Thomas J. DesRosier, attorney-in-fact for Eric D. Shaff
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Eric D. Shaff:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Seres Therapeutics, Inc. CEO and President, Director Common Stock 170K $92.2K $0.54 Nov 18, 2024 Direct
Seres Therapeutics, Inc. CEO and President, Director Restricted Stock Units 70.3K $38K $0.54 Nov 15, 2024 Direct
Seres Therapeutics, Inc. CEO and President, Director Stock Option (Right to Buy) 823K Feb 14, 2024 Direct
Sigilon Therapeutics, Inc. Director Stock Option (Right to Buy) 0 $0.75 Aug 11, 2023 Direct

Insider Reports Filed by Eric D. Shaff

Symbol Company Period Transactions Value $ Form Type Date Filed Role
MCRB Seres Therapeutics, Inc. Nov 15, 2024 3 -$1.35K 4 Nov 19, 2024 CEO and President, Director
MCRB Seres Therapeutics, Inc. Oct 27, 2024 3 -$6.04K 4 Oct 29, 2024 CEO and President, Director
MCRB Seres Therapeutics, Inc. Aug 15, 2024 3 -$2.12K 4 Aug 19, 2024 CEO and President, Director
MCRB Seres Therapeutics, Inc. May 15, 2024 3 -$2.29K 4 May 17, 2024 CEO and President, Director
MCRB Seres Therapeutics, Inc. Feb 14, 2024 6 -$12.5K 4 Feb 16, 2024 CEO and President, Director
MCRB Seres Therapeutics, Inc. Oct 27, 2023 4 -$11.5K 4 Oct 31, 2023 CEO and President, Director
SGTX Sigilon Therapeutics, Inc. Aug 11, 2023 2 -$7.95K 4 Aug 11, 2023 Director
SGTX Sigilon Therapeutics, Inc. May 19, 2023 1 $0 4 May 22, 2023 Director
MCRB Seres Therapeutics, Inc. Feb 3, 2023 2 $0 4 Feb 7, 2023 CEO and President, Director
MCRB Seres Therapeutics, Inc. Jul 5, 2022 1 $200K 4 Jul 6, 2022 CEO and President, Director
SGTX Sigilon Therapeutics, Inc. May 26, 2022 1 $0 4 May 27, 2022 Director
MCRB Seres Therapeutics, Inc. Feb 4, 2022 1 $0 4 Feb 8, 2022 President, CEO, Director
SGTX Sigilon Therapeutics, Inc. Jun 24, 2021 1 $88.6K 4 Jun 28, 2021 Director